040-000-302 Vinpocetine, CAS 42971-09-5

SKU: 040-000-302 Category:
Get A Quote






  I would like to join the mailing list to receive updates from Stanford Chemicals.
*: e-mail address with your company's domain name is preferred. Otherwise, we may not be able to process your inquiry.

Synonyms Apovincaminic Acid ethyl ester, (3α,16α)-eburnamenine-14-carboxylic acid, ethyl ester
Type Derivative of vinca alkaloid vincamine
Source Voacanga Africana/ vinca minor
Keywords Cerebrovascular, dopamine
Related products Losartan Potassium, Horny Goat Weed Extract, Timclol Maleate
Description

Description

Vinpocetine Specifications

Product Name Vinpocetine
CAS Registry Number 42971-09-5
Molecular Formula C22H26N2O2
Molecular Weight 350.5 g/mol
Purity >99 %
Appearance White powder
Package 1kg-25kg
Shelf life 2 years
Functions Treatment of cerebrovascular

Vinpocetine Description

Vinpocetine is a semi-synthetic alkaloid commonly used as an inhibitor of phosphodiesterase 1 (PDE1), blocking the hydrolysis of both cAMP and cGMP. In addition to its use as a selective PDE1 inhibitor in basic research, vinpocetine has diverse cerebral and neurological effects in vivo. Vinpocetine also directly inhibits the kinase activity of IKKβ and blocks TNF-α- and LPS-mediated activation of NF-κB in cells and in vivo. Stanford Chemicals Company (SCC) provides customers with high-quality vinpocetine at a very competitive price.

Vinpocetine is a partially synthesized supplement created from vincamine, which is derived from the seeds of the periwinkle plant.

Vinpocetine Applications

Vinpocetine can be used in the following fields:

  • Laboratory research
  • Treatment of cerebrovascular

 

Reference:

  1. Jeon, K.I., Xu, X., Aizawa, T., et al. Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proceedings of the National Academy of Sciences of the United States of America 107(21), 9795-9800 (2016)
  2. Medina, A.E. Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Front.Neurosci. 5(21), (2011).